| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DB09-1878 |
| P724 | Internet Archive ID | pubmed-PMC2889784 |
| P932 | PMC publication ID | 2889784 |
| P698 | PubMed publication ID | 20357365 |
| P5875 | ResearchGate publication ID | 42806840 |
| P2093 | author name string | Michael W Schwartz | |
| Gregory J Morton | |||
| David A Sarruf | |||
| Jonathan D Fischer | |||
| Joshua P Thaler | |||
| Kayoko Ogimoto | |||
| Jonathan German | |||
| P2860 | cites work | betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c | Q24306279 |
| Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 | ||
| FGF-21 as a novel metabolic regulator | Q24523933 | ||
| FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response | Q24653481 | ||
| Fibroblast growth factor 21: from pharmacology to physiology | Q24658126 | ||
| BetaKlotho is required for metabolic activity of fibroblast growth factor 21 | Q24681531 | ||
| Relevant use of Klotho in FGF19 subfamily signaling system in vivo | Q33667883 | ||
| Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis | Q34019712 | ||
| Hypothalamic K(ATP) channels control hepatic glucose production | Q34413202 | ||
| A brain-liver circuit regulates glucose homeostasis | Q34438321 | ||
| Fibroblast growth factor 21 corrects obesity in mice | Q34805555 | ||
| Energy Expenditure and Fuel Selection in Biological Systems: The Theory and Practice of Calculations Based on Indirect Calorimetry and Tracer Methods | Q35201226 | ||
| Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity | Q37328872 | ||
| Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve | Q37369160 | ||
| Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia | Q37429196 | ||
| The fasting polypeptide FGF21 can enter brain from blood | Q41875742 | ||
| Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice | Q43224118 | ||
| Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. | Q43259536 | ||
| Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. | Q43287114 | ||
| Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. | Q43595875 | ||
| Central administration of oleic acid inhibits glucose production and food intake | Q43867506 | ||
| Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats | Q44001034 | ||
| Diabetes, obesity, and the brain | Q45232063 | ||
| The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity | Q46626373 | ||
| Regulation of blood glucose by hypothalamic pyruvate metabolism | Q46635921 | ||
| Central leptin acutely reverses diet-induced hepatic insulin resistance | Q46774723 | ||
| Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production | Q48145978 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1817-1824 | |
| P577 | publication date | 2010-03-31 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats | |
| P478 | volume | 59 |
| Q38801160 | Adipose Tissue and Energy Expenditure: Central and Peripheral Neural Activation Pathways |
| Q38120479 | An endocrine role for brown adipose tissue? |
| Q36800850 | Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity. |
| Q52889442 | Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles. |
| Q38148473 | Autophagy as a crosstalk mediator of metabolic organs in regulation of energy metabolism |
| Q37550329 | Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice |
| Q39581682 | Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. |
| Q50068190 | Brown and Beige Adipose Tissues in Health and Disease. |
| Q30830123 | CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5. |
| Q34350772 | Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice |
| Q35763646 | Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice |
| Q35601234 | Central angiotensin II has catabolic action at white and brown adipose tissue |
| Q37271698 | Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction |
| Q52650363 | Dietary carbohydrates impair the protective effect of protein restriction against diabetes in NZO mice used as a model of type 2 diabetes. |
| Q36061790 | Dietary restriction in obese children and its relation with eating behavior, fibroblast growth factor 21 and leptin: a prospective clinical intervention study |
| Q39374896 | Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. |
| Q50125932 | Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats |
| Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
| Q36306157 | Erythropoietin (EPO) ameliorates obesity and glucose homeostasis by promoting thermogenesis and endocrine function of classical brown adipose tissue (BAT) in diet-induced obese mice. |
| Q28570740 | FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers |
| Q98906651 | FGF/FGFR signaling in health and disease |
| Q39406663 | FGF1 - a new weapon to control type 2 diabetes mellitus |
| Q47183309 | FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia |
| Q92934465 | FGF21 Levels in Pheochromocytoma/Functional Paraganglioma |
| Q36567992 | FGF21 Regulates Sweet and Alcohol Preference. |
| Q64900381 | FGF21 Signals Protein Status to the Brain and Adaptively Regulates Food Choice and Metabolism. |
| Q34315567 | FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. |
| Q89669025 | FGF21 and the Physiological Regulation of Macronutrient Preference |
| Q27028013 | FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases |
| Q35879505 | FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation |
| Q38645276 | FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes |
| Q58783395 | FGF21 increases water intake, urine output and blood pressure in rats |
| Q28572009 | FGF21 is an endocrine signal of protein restriction |
| Q37485018 | FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice |
| Q37161082 | FGF21 regulates metabolism and circadian behavior by acting on the nervous system |
| Q26785678 | FGF21, energy expenditure and weight loss - How much brown fat do you need? |
| Q39572533 | Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting |
| Q26772751 | Fibroblast Growth Factor Signaling in Metabolic Regulation |
| Q91890308 | Fibroblast Growth Factor-21 Controls Dietary Protein Intake in Male Mice |
| Q64235887 | Fibroblast Growth Factors in Depression |
| Q35405521 | Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity |
| Q38058339 | Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. |
| Q35794417 | Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice |
| Q47685213 | Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice. |
| Q35266374 | Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes |
| Q34450441 | Fibroblast growth factor 21 is not required for the reductions in circulating insulin-like growth factor-1 or global cell proliferation rates in response to moderate calorie restriction in adult mice |
| Q36796145 | Fibroblast growth factor 21 mediates specific glucagon actions |
| Q39017842 | Fibroblast growth factor 21 night watch: advances and uncertainties in the field |
| Q37736500 | Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2/Nesfatin-1 neurons to produce satiety under fed states |
| Q38201778 | Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases |
| Q36486182 | Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. |
| Q40895648 | Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. |
| Q92503336 | Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application |
| Q34559840 | Genetic determinants of atherosclerosis, obesity, and energy balance in consomic mice |
| Q30412686 | Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake |
| Q35929495 | Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response |
| Q89063903 | Homeostatic sensing of dietary protein restriction: A case for FGF21 |
| Q42870834 | Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet |
| Q39156563 | Impact of Fibroblast Growth Factors 19 and 21 in Bariatric Metabolism. |
| Q43589056 | Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity |
| Q56964468 | Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein |
| Q24632545 | Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo |
| Q26823319 | Inventing new medicines: The FGF21 story |
| Q38475978 | Latest approaches for the treatment of obesity. |
| Q35060716 | Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms |
| Q41421048 | Low protein-induced increases in FGF21 drive UCP1-dependent metabolic but not thermoregulatory endpoints |
| Q34766261 | Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes |
| Q38120144 | Mechanisms underlying weight loss after bariatric surgery |
| Q36746670 | Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis |
| Q33685319 | Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues |
| Q38066238 | Metabolic syndrome in youth: current insights and novel serum biomarkers |
| Q63252846 | Methionine restriction prevents onset of type 2 diabetes in NZO mice |
| Q47796012 | Microfluidic systems for studying dynamic function of adipocytes and adipose tissue |
| Q98159132 | Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21 |
| Q27005992 | Neural control of energy balance: translating circuits to therapies |
| Q26751836 | Non-sympathetic control of brown adipose tissue |
| Q34325630 | Novel locus including FGF21 is associated with dietary macronutrient intake |
| Q36589260 | Obesity surgery: happy with less or eternally hungry? |
| Q37112476 | PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. |
| Q90315934 | Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain |
| Q38061797 | Peripheral signalling involved in energy homeostasis control |
| Q35581474 | Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice |
| Q48107382 | Pharmacokinetics, tissue distribution and excretion of FGF-21 following subcutaneous administration in rats. |
| Q51748272 | Photoperiodic regulation of FGF21 production in the Siberian hamster. |
| Q42855258 | Play down protein to play up metabolism? |
| Q38688679 | Potential roles of fibroblast growth factor 21 in the brain |
| Q88993329 | Protective Effects of Fibroblast Growth Factor 21 Against Amyloid-Beta1-42-Induced Toxicity in SH-SY5Y Cells |
| Q100532878 | Protein metabolism and related body function - mechanistic approaches and health consequences |
| Q28088330 | Protein-dependent regulation of feeding and metabolism |
| Q28485340 | Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes |
| Q35218087 | Receptor antibodies as novel therapeutics for diabetes |
| Q36635907 | Recruitment of histone methyltransferase G9a mediates transcriptional repression of Fgf21 gene by E4BP4 protein |
| Q33835303 | Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster. |
| Q94560979 | Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands |
| Q28070054 | Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state |
| Q90468275 | Regulation of metabolic health by essential dietary amino acids |
| Q36930792 | Role of GCN2-Independent Signaling Through a Noncanonical PERK/NRF2 Pathway in the Physiological Responses to Dietary Methionine Restriction. |
| Q37278829 | Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice. |
| Q40280560 | Sleep Duration and Cardiometabolic Risk Among Chinese School-aged Children: Do Adipokines Play a Mediating Role? |
| Q42132608 | Systemic control of brown fat thermogenesis: integration of peripheral and central signals |
| Q93180147 | The FGF metabolic axis |
| Q91842434 | The Hypothalamic Arcuate Nucleus-Median Eminence Is a Target for Sustained Diabetes Remission Induced by Fibroblast Growth Factor 1 |
| Q26865368 | The brain and brown fat |
| Q91951425 | The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform |
| Q38750211 | The emerging role of fibroblast growth factor 21 in diabetic nephropathy |
| Q36127934 | The impact of polyphenols on chondrocyte growth and survival: a preliminary report |
| Q55513236 | The role of FGF21 in type 1 diabetes and its complications. |
| Q53682459 | The role of adipokines in skeletal muscle inflammation and insulin sensitivity. |
| Q98238156 | The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q34787051 | Thermogenic activation induces FGF21 expression and release in brown adipose tissue. |
| Q34778879 | Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. |
| Q54468633 | Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. |
| Q37220495 | Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3 |
| Q92524593 | Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster |
| Q36248720 | βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism |
Search more.